Medication info
ARBI-SD Tablet

ARBI-SD Tablet

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
Round film-coated tablet with reddish-yellow color
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201100812 · Approved 2011.02.21 · Insurance code 647803500

Summary

Main use
Treatment of essential hypertension not adequately controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Before administering this drug, it is recommended to adjust the dose using olmesartan medoxomil or hydrochlorothiazide alone. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this drug once daily, with or without food. Adjust the dose at intervals of 2~4 weeks, taking the patient's blood pressure response into consideration. A marked reduction in blood pressure may occur when olmesartan medoxomil is added or patients are switched to this drug (olmesartan medoxomil/hydrochlorothiazide) in patients taking high doses of hydrochlorothiazide as a single agent or in patients with volume depletion or hyponatremia. In such cases, reduce the hydrochlorothiazide dose to 12.5mg before adding olmesartan medoxomil. <Elderly patients> For elderly patients, start with the lowest dose and use caution when adjusting the dose, taking into account renal or cardiac function, comorbidities, and other concomitant medications. <Patients with renal impairment> This drug (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild to moderate renal impairment (creatinine clearance>30mL/min). This drug (olmesartan medoxomil/hydrochlorothiazide) should not be administered to patients with more severe renal impairment, as loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic impairment> Use of this drug is not recommended in patients with hepatic impairment because there is no experience with its use in these patients.
Child dose
Safety and efficacy in children have not been established.

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not adequately controlled with monotherapy

  • Essential hypertension
View approved original text

Olmesartan Medoxomil and Hydrochlorothiazide help effectively lower blood pressure in patients with essential hypertension who have difficulty controlling blood pressure with either agent alone. Continuous blood pressure management is important to reduce the risk of cardiovascular complications. These two agents work by either dilating blood vessels or exerting diuretic effects to control blood pressure. If necessary, the combination of both drugs can enhance the therapeutic effect. Therefore, Olmesartan Medoxomil and Hydrochlorothiazide are used in the treatment of essential hypertension.

How to take

Adult dose

Before administering this drug, it is recommended to adjust the dose using olmesartan medoxomil or hydrochlorothiazide alone. If blood pressure is not adequately controlled with the individual components, administer 1 tablet of this drug once daily, with or without food. Adjust the dose at intervals of 2~4 weeks, taking the patient's blood pressure response into consideration. A marked reduction in blood pressure may occur when olmesartan medoxomil is added or patients are switched to this drug (olmesartan medoxomil/hydrochlorothiazide) in patients taking high doses of hydrochlorothiazide as a single agent or in patients with volume depletion or hyponatremia. In such cases, reduce the hydrochlorothiazide dose to 12.5mg before adding olmesartan medoxomil. <Elderly patients> For elderly patients, start with the lowest dose and use caution when adjusting the dose, taking into account renal or cardiac function, comorbidities, and other concomitant medications. <Patients with renal impairment> This drug (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild to moderate renal impairment (creatinine clearance>30mL/min). This drug (olmesartan medoxomil/hydrochlorothiazide) should not be administered to patients with more severe renal impairment, as loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic impairment> Use of this drug is not recommended in patients with hepatic impairment because there is no experience with its use in these patients.

Child dose

Safety and efficacy in children have not been established.

Precautions

This medication can cause serious harm or death to the fetus or newborn if taken during the second or third trimester of pregnancy, so treatment should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to this medication’s ingredients, those with specific kidney and liver diseases, pregnant or breastfeeding women, and those with certain electrolyte imbalances or other specific conditions should not take this medication. Patients with decreased blood volume or impaired kidney function may experience hypotension or kidney function deterioration while taking this medication, so they should be monitored closely. This medication can cause electrolyte imbalances, particularly changes in potassium, sodium, magnesium, and calcium levels, so regular blood tests are necessary. During treatment, symptoms such as dizziness or headaches may occur; in severe cases, consult a healthcare provider. Interactions may occur when taken with other medications, so inform your healthcare provider of any drugs currently being taken. This medication may cause the skin to become sensitive to sunlight, so limit sun exposure and appropriate skin protection is necessary. Breastfeeding women should consult a physician before taking this medication, as it can pass into breast milk and affect the infant. In elderly patients or children, the safety and efficacy of this medication have not been fully established, so exercise special caution. In case of overdose, symptoms such as hypotension, electrolyte imbalance, and dehydration may occur; seek appropriate treatment immediately.

Side effects

Nausea, hyperuricemia, dizziness, upper respiratory infection, headache, urinary tract infection, chest pain, low back pain, peripheral edema, abdominal pain, dyspepsia, gastroenteritis, diarrhea, increased AST, increased GGT, increased ALT, hyperlipidemia, increased creatine phosphokinase, hyperglycemia, arthritis, arthralgia, myalgia, cough, rash, hematuria, facial edema, weakness, angioedema, anaphylactic reaction, vomiting, rhabdomyolysis, acute renal failure, increased blood creatinine, hair loss, pruritus, urticaria, palpitations, vertigo, fatigue, drowsiness, emotional blunting, restlessness, interstitial pneumonia, pulmonary edema, acute respiratory distress syndrome, orthostatic hypotension, arrhythmia, transient blurred vision, jaundice, choroidal effusion, cholestasis, hepatitis, acute cholecystitis, necrotizing vasculitis, interstitial pneumonia, dyspnea, facial flushing, photosensitivity, hypokalemia, hyponatremia, hypomagnesemia, hydrochloric alkalosis, hypercalcemia, thrombocytopenia, leukopenia, aplastic anemia, hemolytic anemia, purpura, anorexia, thirst, abdominal discomfort, constipation, abdominal colic, pancreatitis, jaundice, sialadenitis, dry mouth, Stevens-Johnson syndrome, erythema multiforme, exfoliative dermatitis, toxic epidermal necrolysis, malaise, nasal congestion, erectile dysfunction, systemic lupus erythematosus flare, parathyroid disorder, muscle cramps, sensory disturbances, frailty, epistaxis, asthma, chronic malabsorption syndrome-like intestinal disease, intestinal vascular edema

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to avoid exposure to air and moisture, and it is recommended to keep it at room temperature between 1 to 25 degrees Celsius. This storage method helps maintain the medication's efficacy and prevents deterioration.

Appearance and packaging

Appearance

Round film-coated tablet with reddish-yellow color

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.